- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Gary Lyman, MD, MPH: The Biosimilar Approval Pathway
Gary Lyman, MD, MPH, of the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, describes the biosimilar approval pathway in the United States.
Transcript:
Biosimilars are approved by the FDA based on a different mechanism than the original products. So the original biologics, some of which go back 20 years, were approved as an originator, an innovator drug. They had to provide not only the preclinical data but several randomized controlled trials demonstrating efficacy and safety.
Obviously that's an extremely costly process, and to facilitate the development of biosimilars, a more expedited process was put in place by the FDA a few years ago which put much more emphasis on the molecular characteristics, structure, and its biologic behavior in the patient: pharmacokinetics, pharmacodynamics, whether there are antibodies formed, immunogenicity, all these things to demonstrate that it’s very similar, highly similar to the original product, but without the necessity of going through the multimillion-dollar, large, randomized phase 3 trials.
Some some of the biosimilars have done that anyway, but the idea here is to reduce the cost of development so that that cost reduction could be passed on in terms of lower pricing and greater competition in the marketplace. So it's really a focus on the preclinical work and the safety in patients, and the assumption that if it's virtually the same molecule, same mechanism of action, doesn't have any safety concerns, it will function essentially the same as the original biologic product.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
